Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1500 of 2529 entries
View as:

Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

Phase: N/A Priority: Normal
NCT ID: NCT01840410 Org: User:
Start: 09/30/13 End: 11/30/15 Due: 11/30/16

Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

Phase: N/A Priority: Normal
NCT ID: NCT05375097 Org: User:
Start: 07/03/20 End: 05/14/21 Due: 05/14/22

Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT01593787 Org: User:
Start: 05/31/12 End: 03/31/13 Due: 03/31/14

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05803941 Org: User:
Start: 08/14/23 End: 07/21/33 Due: 07/21/34

Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01202903 Org: User:
Start: 09/30/10 End: 10/31/13 Due: 10/31/14

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04524000 Org: User:
Start: 01/08/21 End: 10/02/27 Due: 10/02/28

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04903197 Org: User:
Start: 01/24/22 End: 02/24/25 Due: 02/24/26

Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.

Phase: N/A Priority: Normal
NCT ID: NCT03074357 Org: User:
Start: 04/04/17 End: 03/23/18 Due: 03/23/19

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

Phase: N/A Priority: Normal
NCT ID: NCT00124709 Org: User:
Start: 10/31/03 End: 11/30/08 Due: 11/30/09

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT01007968 Org: User:
Start: 03/31/10 End: 11/30/12 Due: 11/30/13

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Phase: N/A Priority: Normal
NCT ID: NCT00845871 Org: User:
Start: 05/31/09 End: 08/31/10 Due: 08/31/11

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Phase: N/A Priority: Normal
NCT ID: NCT01387958 Org: User:
Start: 07/31/11 End: 02/29/12 Due: 02/28/13

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT06184360 Org: User:
Start: 05/31/22 End: 12/16/22 Due: 12/16/23

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Phase: N/A Priority: Normal
NCT ID: NCT00061750 Org: User:
Start: 05/31/03 End: - Due: -

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Phase: N/A Priority: Normal
NCT ID: NCT02913105 Org: User:
Start: 10/24/16 End: 09/19/18 Due: 09/19/19

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

Phase: N/A Priority: Normal
NCT ID: NCT02032173 Org: User:
Start: 05/19/14 End: 04/29/15 Due: 04/29/16

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00742027 Org: User:
Start: 09/16/08 End: 08/12/13 Due: 08/12/14

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00239785 Org: User:
Start: 04/30/03 End: - Due: -

Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00504543 Org: User:
Start: 07/31/07 End: 04/30/11 Due: 04/30/12

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT01979601 Org: User:
Start: 12/31/10 End: 11/30/11 Due: 11/30/12

Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME

Phase: N/A Priority: Normal
NCT ID: NCT02262260 Org: User:
Start: 12/12/14 End: 09/12/17 Due: 09/12/18

Extension in AS: Sustainability of Benefits, Safety and Tolerability

Phase: N/A Priority: Normal
NCT ID: NCT01863732 Org: User:
Start: 11/06/13 End: 03/16/18 Due: 03/16/19

NVA237 Versus Placebo 12-week Efficacy Study

Phase: N/A Priority: Normal
NCT ID: NCT01709864 Org: User:
Start: 11/30/12 End: 10/31/13 Due: 10/31/14

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01079143 Org: User:
Start: 09/30/09 End: 06/30/12 Due: 06/30/13

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Phase: N/A Priority: Normal
NCT ID: NCT00582426 Org: User:
Start: 04/30/08 End: 09/30/10 Due: 09/30/11